Search Results - Netanel A. Horowitz

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy by Nurit Horesh, Netanel A. Horowitz

    Published in Rambam Maimonides Medical Journal (2014-10-01)
    Get full text
    Article


  2. 2

    Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospect... by Yael Morgenstern, Shlomzion Aumann, Neta Goldschmidt, Moshe E. Gatt, Boaz Nachmias, Netanel A. Horowitz

    Published in Cancer Medicine (2021-12-01)
    Get full text
    Article


  3. 3

    Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantation—can preemptive detection of John Cunningham virus be useful? by Irit Avivi, Talya Wittmann, Israel Henig, Zipora Kra-Oz, Moran Szwarcwort Cohen, Tsila Zuckerman, Netanel A. Horowitz, Noam Benyamini

    Get full text
    Article


  4. 4

    Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity by Ben Varon, Amir Grau, Noga Setter Marco, Anwar Khatib, Tsofia Levi, Riva Fineman, Inna Tzoran, Nivin Mustafa, Tsila Zuckerman, Netanel A. Horowitz, Noa Lavi, Rostislav Novak, Ofrat Beyar-Katz

    Published in Annals of Hematology (2026-04-01)
    Get full text
    Article


  5. 5

    Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster Dose by Avi Magid, Khetam Hussein, Halima Dabaja-Younis, Moran Szwarcwort-Cohen, Ronit Almog, Michal Mekel, Avi Weissman, Gila Hyams, Vardit Gepstein, Netanel A. Horowitz, Hagar Cohen Saban, Jalal Tarabeia, Michael Halberthal, Yael Shachor-Meyouhas

    Published in Antibodies (2024-08-01)
    Get full text
    Article


  6. 6

    BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study by Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren-Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, Olga Nudelman, Sigal Tavor, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, Ruth Ben Yakar, Jacob M. Rowe

    Published in Blood Advances (2019-11-01)
    Get full text
    Article


  7. 7

    Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies by Ronit Gurion, Uri Rozovski, Gilad Itchaki, Anat Gafter-Gvili, Chiya Leibovitch, Pia Raanani, Haim Ben-Zvi, Moran Szwarcwort, Mor Taylor-Abigadol, Eldad J. Dann, Nurit Horesh, Tsofia Inbar, Inna Tzoran, Noa Lavi, Riva Fineman, Shimrit Ringelstein-Harlev, Netanel A. Horowitz

    Published in Haematologica (2021-07-01)
    Get full text
    Article


  8. 8

    A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma by Graham P. Collins, Toby A. Eyre, Debora Schmitz-Rohmer, William Townsend, Rakesh Popat, Lisa Giulino-Roth, Paul A. Fields, Fatime Krasniqi, Carole Soussain, Anastasios Stathis, Nebojsa Andjelkovic, David Cunningham, Danijela Mandic, Sinisa Radulovic, Ivan Tijanic, Netanel A. Horowitz, Sabira Kurtovic, Elisabeth Schorb, Christian Schmidt, Saša Dimitrijević, Martin Dreyling

    Published in HemaSphere (2021-11-01)
    Get full text
    Article


  9. 9

    An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab by Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh‐Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. Chemaly, Juan Carlos Ramos‐Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)

    Published in Cancer Medicine (2024-02-01)
    Get full text
    Article


  10. 10

    Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study by Hovav Azuly, Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh-Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. Chemaly, Juan Carlos Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher, on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)

    Published in Infectious Diseases and Therapy (2024-12-01)
    Get full text
    Article


Search Tools: